Eloxatin Has 38% Share Of First-Line Colorectal Cancer Market, Sanofi Says
Executive Summary
Sanofi-Synthelabo's Eloxatin has taken a greater than one-third share of the first-line advanced colorectal cancer market from Camptosar ahead of FDA approval, Exec VP-Operations Hanspeter Spek said
You may also be interested in...
Sanofi Eloxatin first-line approval
Sanofi-Synthelabo's Eloxatin (oxaliplatin) approved Jan. 9 for first-line treatment of advanced colorectal cancer, in combination with 5-fluorouracil and leucovorin. Eloxatin was cleared August 2002 as second-line treatment in combination with 5-FU/leucovorin; Sanofi told investors in September that Eloxatin had captured 38% of the first-line market ahead of approval (1"The Pink Sheet" Sept. 8, 2003, p. 26)...
Sanofi Eloxatin first-line approval
Sanofi-Synthelabo's Eloxatin (oxaliplatin) approved Jan. 9 for first-line treatment of advanced colorectal cancer, in combination with 5-fluorouracil and leucovorin. Eloxatin was cleared August 2002 as second-line treatment in combination with 5-FU/leucovorin; Sanofi told investors in September that Eloxatin had captured 38% of the first-line market ahead of approval (1"The Pink Sheet" Sept. 8, 2003, p. 26)...
Sanofi Eloxatin First-Line Colorectal Cancer Data Will Be Submitted By 2003
Sanofi-Synthelabo Eloxatin first-line data in advanced colonic and rectal adenocarcinoma will be submitted to FDA by the third quarter of 2003, following oxaliplatin's approval as second-line use